Blueprint Medicines Competitors and Similar CompaniesClear all

Blueprint Medicines's competitors and similar companies include Deciphera Pharmaceuticals, AstraZeneca United States, Halozyme Therapeutics, Ohm Oncology and Repare Therapeutics.
Blueprint Medicines
Blueprint Medicines
Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders.
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer.
AstraZeneca United States
AstraZeneca United States
AstraZeneca United States is a biopharmaceutical company.
Halozyme Therapeutics
Halozyme Therapeutics
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
Ohm Oncology
Ohm Oncology
Ohm Oncology is a drug development company committed to treating drug-resistant neoplasms and cancers with multi-mechanism compounds.
Repare Therapeutics
Repare Therapeutics
Repare Therapeutics is a company that develops oncology drugs for patients that target specific vulnerabilities of tumor cells.
Founding Date
Founding Date
2011
Founding Date
2003
Founding Date
N/A
Founding Date
1998
Founding Date
2015
Founding Date
2016
Type
Type
Public
Type
Public
Type
Subsidiary
Type
Public
Type
Private
Type
Public
Tags
Locations
Locations
Cambridge, US HQ
Amsterdam, NL
Lugano, CH
Zug, CH
Locations
Waltham, US HQ
Lawrence, US
Locations
Wilmington, US HQ
Gaithersburg, US
Locations
San Diego, US HQ
Locations
Austin, US HQ
Locations
Montréal, CA HQ
Cambridge, US
Employees
Employees
6552% increase
Employees
35037% increase
Employees
N/A
Employees
373157% increase
Employees
167% decrease
Employees
179
Valuation ($)
Valuation ($)
5.3 b
Valuation ($)
2.2 b
Valuation ($)
N/A
Valuation ($)
6.4 b
Valuation ($)
N/A
Valuation ($)
152.4 m

Financial

Revenue (est.)
Revenue (est.)
$249.4m (FY, 2023)
Revenue (est.)
$163.4m (FY, 2023)
Revenue (est.)
N/A
Revenue (est.)
$829.3m (FY, 2023)
Revenue (est.)
N/A
Revenue (est.)
$51.1m (FY, 2023)
Cost of goods
Cost of goods
$8.5m (FY, 2023)
Cost of goods
$3.7m (FY, 2023)
Cost of goods
N/A
Cost of goods
$192.4m (FY, 2023)
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
$240.8m (FY, 2023)
Gross profit
$159.6m (FY, 2023)
Gross profit
N/A
Gross profit
$636.9m (FY, 2023)
Gross profit
N/A
Gross profit
$51.1m (FY, 2023)
Net income
Net income
($507m) (FY, 2023)
Net income
($194.9m) (FY, 2023)
Net income
N/A
Net income
$281.6m (FY, 2023)
Net income
N/A
Net income
($93.8m) (FY, 2023)

Operating

Patent Applications
Patent Applications
N/A
Patent Applications
49 (Aug, 2017)
Patent Applications
N/A
Patent Applications
50 (FY, 2020)
Patent Applications
N/A
Patent Applications
N/A
Patents (US)
Patents (US)
N/A
Patents (US)
11 (Aug, 2017)
Patents (US)
N/A
Patents (US)
43 (FY, 2020)
Patents (US)
N/A
Patents (US)
N/A

Funding

Total funding raised
Total funding raised
$ 1.7b
Total funding raised
$ 714m
Total funding raised
N/A
Total funding raised
$ 171.9m
Total funding raised
N/A
Total funding raised
$ 150.5m
For sources of this data, please see the company profile

View Company Profiles

Deciphera Pharmaceuticals
HQ
Waltham, US
Employees
350↑ 37% increase

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer.

View company
AstraZeneca United States
HQ
Wilmington, US

AstraZeneca United States is a biopharmaceutical company.

View company
Halozyme Therapeutics
HQ
San Diego, US
Employees
373

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.

View company
Ohm Oncology
HQ
Austin, US
Employees
1

Ohm Oncology is a drug development company committed to treating drug-resistant neoplasms and cancers with multi-mechanism compounds.

View company